Simris Group (SIMRIS) Q1 2025 earnings summary

Executive summary

• Net revenue for Q1 2025 fell 69% year-over-year to SEK 159k, while EBITDA loss improved 30% to SEK -3,724k and EBIT loss improved 19% to SEK -7,288k.

• Scientific progress included in-vitro efficacy of a microcystin payload nearly matching a leading ADC for HER2-positive breast cancer, setting a benchmark for further studies.

• The company remains focused on developing next-generation payloads for targeted cancer therapies and has deepened preclinical collaborations.

Financial highlights

• Result before tax improved 32% year-over-year to SEK -6,795k.

• Cash flow from operating activities improved 3% to SEK -5,284k; cash at period end was SEK 2,998k, up from SEK 185k a year earlier.

• Equity at period end was SEK -1,071k, down from SEK 17,312k; solidity was -0.7%.

• Inventory at period end was SEK 481k, all related to Simris Biologics.

Outlook and guidance

• Board warns current cash reserves may not cover operations through year-end; active efforts underway to secure additional funding via debt, investment, or partnerships.

• Company remains reliant on external funding to continue operations and growth plans.